DE602004023886D1 - Botulintoxin-Therapie für Hauterkrankungen - Google Patents

Botulintoxin-Therapie für Hauterkrankungen

Info

Publication number
DE602004023886D1
DE602004023886D1 DE602004023886T DE602004023886T DE602004023886D1 DE 602004023886 D1 DE602004023886 D1 DE 602004023886D1 DE 602004023886 T DE602004023886 T DE 602004023886T DE 602004023886 T DE602004023886 T DE 602004023886T DE 602004023886 D1 DE602004023886 D1 DE 602004023886D1
Authority
DE
Germany
Prior art keywords
botulintoxin
therapy
skin diseases
hammertoe
keratose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004023886T
Other languages
English (en)
Inventor
Eric R First
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE602004023886D1 publication Critical patent/DE602004023886D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
DE602004023886T 2003-12-09 2004-12-08 Botulintoxin-Therapie für Hauterkrankungen Active DE602004023886D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/731,973 US8048423B2 (en) 2003-12-09 2003-12-09 Botulinum toxin therapy for skin disorders

Publications (1)

Publication Number Publication Date
DE602004023886D1 true DE602004023886D1 (de) 2009-12-10

Family

ID=34634457

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004023886T Active DE602004023886D1 (de) 2003-12-09 2004-12-08 Botulintoxin-Therapie für Hauterkrankungen
DE602004008329T Active DE602004008329T2 (de) 2003-12-09 2004-12-08 Botulinustoxin-therapie für hauterkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004008329T Active DE602004008329T2 (de) 2003-12-09 2004-12-08 Botulinustoxin-therapie für hauterkrankungen

Country Status (10)

Country Link
US (1) US8048423B2 (de)
EP (2) EP1691830B1 (de)
JP (1) JP4937758B2 (de)
AT (2) ATE369874T1 (de)
AU (1) AU2004296870B2 (de)
BR (1) BRPI0417493B8 (de)
CA (1) CA2549550C (de)
DE (2) DE602004023886D1 (de)
ES (2) ES2289591T3 (de)
WO (1) WO2005056050A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20080008777A1 (en) * 2004-02-12 2008-01-10 Philip Radovic Methods of treating a bunion
US7276244B2 (en) * 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US8497081B2 (en) 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
WO2005082096A2 (en) * 2004-02-24 2005-09-09 Allergan, Inc. Botulinum toxin screening assays
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
WO2006034404A2 (en) * 2004-09-23 2006-03-30 Toxcure, Inc. Treating neoplasms with neurotoxin
AU2005288758A1 (en) * 2004-09-27 2006-04-06 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins for use in tissue healing
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
EP2661276B1 (de) * 2011-01-07 2017-08-02 Revance Therapeutics, Inc. Topische zusammensetzung enthaltend botulinus toxin und ein farbstoff
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
EP2976060B1 (de) 2013-03-22 2016-10-26 Lipotec, S.A. Exopolysaccharide zur behandlung und/oder zum schutz der haut, schleimhäute und/oder nägel
CA3055380A1 (en) 2017-03-13 2018-09-20 Philip Andrew RADOVIC Neuromuscular toxin for use in treating an abnormality of the first metatarsophalangeal joint of a foot
CA3065542A1 (en) * 2017-05-31 2018-12-06 Allergan, Inc. Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
AU2431995A (en) * 1994-05-09 1995-11-29 William J. Binder Method for reduction of headache pain
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
ATE216589T1 (de) * 1996-11-27 2002-05-15 William J Binder Neurotoxine zur behandlung von hauterkrankungen bei säugetieren
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
MXPA01004254A (es) * 1998-10-27 2002-04-24 Mayo Foundation Metodos para intensificar la curacion de heridas.
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
DK1411978T3 (da) 2001-07-27 2009-01-05 Univ Louisiana State Botulinum-toksin ved behandlingen eller forebyggelsen af acne
DE10146647A1 (de) * 2001-09-21 2003-04-24 Marc Heckmann Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis
WO2004000389A2 (en) * 2002-06-25 2003-12-31 Sung-Yun Kwon Rapidly dissolving micro-perforator for drug delivery and other applications
US6945952B2 (en) * 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
AU2004216901B2 (en) * 2003-03-06 2009-11-12 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin

Also Published As

Publication number Publication date
EP1691830A1 (de) 2006-08-23
BRPI0417493B8 (pt) 2021-05-25
ATE446769T1 (de) 2009-11-15
WO2005056050A1 (en) 2005-06-23
US8048423B2 (en) 2011-11-01
ES2289591T3 (es) 2008-02-01
JP4937758B2 (ja) 2012-05-23
JP2007513964A (ja) 2007-05-31
EP1691830B1 (de) 2007-08-15
AU2004296870B2 (en) 2010-05-20
DE602004008329T2 (de) 2008-05-08
BRPI0417493A (pt) 2007-05-29
CA2549550C (en) 2012-07-17
ES2335310T3 (es) 2010-03-24
ATE369874T1 (de) 2007-09-15
EP1820510A1 (de) 2007-08-22
EP1820510B1 (de) 2009-10-28
US20050123567A1 (en) 2005-06-09
AU2004296870A1 (en) 2005-06-23
BRPI0417493B1 (pt) 2018-11-13
DE602004008329D1 (de) 2007-09-27
CA2549550A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
ATE446769T1 (de) Botulintoxin-therapie für hauterkrankungen
PT1492561E (pt) Metodo para tratar disturbios da glandula mamaria
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
ATE439868T1 (de) Targetingmittel für molekulare bilderzeugung
BRPI0412763A (pt) formas anidras, hidratadas ou solvatadas de um composto, forma cristalina, composição farmacêutica, e, método para o tratamento ou a profilaxia de distúrbios
PL415000A1 (pl) Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do wytwarzania leku do leczenia litych guzów ośrodkowego układu nerwowego
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
HK1082203A1 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
BRPI0417101A (pt) uso de compostos de peptìdeo para tratamento de dor neuropática central
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
MY157745A (en) Method of treating of demyelinating diseases or conditions
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
SE0101082D0 (sv) Novel use
NO20032406D0 (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
WO2003084476A3 (en) Treatment of lung disorder
SE0002739D0 (sv) New use
DE60335093D1 (de) Verwendung von nichtantibakteriellen tetrazyklin-analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen
BRPI0509478A (pt) tratamento de ferida por pressão
PT1133295E (pt) Utilizacao da nicergolina no tratamento da espasticidade
BRPI0408322A (pt) uso de um fibrato e orlistat para o tratamento da obesidade
NZ606828A (en) Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
PT1235573E (pt) Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais

Legal Events

Date Code Title Description
8364 No opposition during term of opposition